Trial Profile
Long Term Follow-up Study to Evaluate the Safety of Repeated Intra-Articular Injection of SI-613 in Patients with Osteoarthritis.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Diclofenac-Eatlhyaluronate (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical; Seikagaku Corporation
- 23 Mar 2021 According to an Ono Pharmaceutical media release, Seikagaku has obtained from the Ministry of Health, Labour and Welfare (MHLW) a manufacturing and marketing approval in Japan for JOYCLU 30mg Intra-articular Injection (diclofenac etalhyaluronate sodium; JOYCLU) for the indication of osteoarthritis (knee joint and hip joint).The approval is based on the results of three Phase III clinical studies conducted in Japan (JapicCTI173537,JapicCTI173678 and JapicCTI183855).
- 06 Jan 2020 According to an Ono Pharmaceutical media release, company has submitted a new drug application ("NDA") for manufacturing and marketing approval for ONO-5704/SI-613 in Japan, for the treatment of osteoarthritis (knee joint, hip joint and ankle joint). The NDA is based on the results of three Phase III clinical studies conducted with the Product in Japan.
- 06 Sep 2018 Status changed from recruiting to active, no longer recruiting.